Neoprobe Lymphoseek trial progresses

Gamma camera probe developer Neoprobe said that a multicenter phase II clinical study of its Lymphoseek radioactive targeting agent has yielded positive preliminary results.

In the trial, localization of Lymphoseek to lymphoid tissue was observed in over 94% of the sentinel lymph node biopsy (SNLB) procedures performed in patients with either breast cancer or melanoma, according to the Dublin, OH-based firm. Neoprobe said it's now preparing to submit its phase III clinical trial protocol to the U.S. Food and Drug Administration (FDA).

By staff writers
June 21, 2007

Related Reading

Neoprobe's Q1 sales slip, loss edges up, May 1, 2007

Neoprobe Lymphoseek trial moves forward, March 5, 2007

Neoprobe gets FDA nod for more Lymphoseek trials, January 17, 2007

Neoprobe debuts Bluetooth probe, October 10, 2006

Neoprobe, Estech ink distribution deal, September 11, 2006

Copyright © 2007

Page 1 of 436
Next Page